WO2005082070A3 - Compositions and methods for the systemic treatment of arthritis - Google Patents

Compositions and methods for the systemic treatment of arthritis Download PDF

Info

Publication number
WO2005082070A3
WO2005082070A3 PCT/US2005/006200 US2005006200W WO2005082070A3 WO 2005082070 A3 WO2005082070 A3 WO 2005082070A3 US 2005006200 W US2005006200 W US 2005006200W WO 2005082070 A3 WO2005082070 A3 WO 2005082070A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
arthritis
compositions
systemic treatment
autoinflammation
Prior art date
Application number
PCT/US2005/006200
Other languages
French (fr)
Other versions
WO2005082070A2 (en
Inventor
Jacques Banchereau
Virginia Pascual
Original Assignee
Baylor Res Inst
Jacques Banchereau
Virginia Pascual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34910974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005082070(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baylor Res Inst, Jacques Banchereau, Virginia Pascual filed Critical Baylor Res Inst
Priority to EP05723881.8A priority Critical patent/EP1720893B1/en
Priority to CN2005800128324A priority patent/CN1946734B/en
Priority to DK05723881.8T priority patent/DK1720893T3/en
Priority to JP2007501027A priority patent/JP4989456B2/en
Priority to ES05723881.8T priority patent/ES2523147T3/en
Priority to AU2005216298A priority patent/AU2005216298B2/en
Priority to CA2557508A priority patent/CA2557508C/en
Publication of WO2005082070A2 publication Critical patent/WO2005082070A2/en
Publication of WO2005082070A3 publication Critical patent/WO2005082070A3/en
Priority to AU2010214641A priority patent/AU2010214641C1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin

Abstract

The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.
PCT/US2005/006200 2004-02-26 2005-02-25 Compositions and methods for the systemic treatment of arthritis WO2005082070A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP05723881.8A EP1720893B1 (en) 2004-02-26 2005-02-25 Compositions and methods for the systemic treatment of arthritis
CN2005800128324A CN1946734B (en) 2004-02-26 2005-02-25 Compositions and methods for the systemic treatment of arthritis
DK05723881.8T DK1720893T3 (en) 2004-02-26 2005-02-25 COMPOSITIONS AND PROCEDURES FOR THE SYSTEMIC TREATMENT OF ARTHRITIS
JP2007501027A JP4989456B2 (en) 2004-02-26 2005-02-25 Compositions and methods for systemic treatment of arthritis
ES05723881.8T ES2523147T3 (en) 2004-02-26 2005-02-25 Compositions and methods for the systemic treatment of arthritis
AU2005216298A AU2005216298B2 (en) 2004-02-26 2005-02-25 Compositions and methods for the systemic treatment of arthritis
CA2557508A CA2557508C (en) 2004-02-26 2005-02-25 Compositions and methods for the systemic treatment of arthritis
AU2010214641A AU2010214641C1 (en) 2004-02-26 2010-08-25 Compositions and methods for the systemic treatment of arthritis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54803304P 2004-02-26 2004-02-26
US60/548,033 2004-02-26

Publications (2)

Publication Number Publication Date
WO2005082070A2 WO2005082070A2 (en) 2005-09-09
WO2005082070A3 true WO2005082070A3 (en) 2006-02-02

Family

ID=34910974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/006200 WO2005082070A2 (en) 2004-02-26 2005-02-25 Compositions and methods for the systemic treatment of arthritis

Country Status (9)

Country Link
US (13) US7615212B2 (en)
EP (2) EP2784090A1 (en)
JP (3) JP4989456B2 (en)
CN (1) CN1946734B (en)
AU (2) AU2005216298B2 (en)
CA (1) CA2557508C (en)
DK (1) DK1720893T3 (en)
ES (1) ES2523147T3 (en)
WO (1) WO2005082070A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1295611E (en) * 2000-06-20 2010-09-14 Dainippon Sumitomo Pharma Co Oligonucleotide-transferring preparations
WO2003000297A1 (en) * 2001-06-20 2003-01-03 Sumitomo Pharmaceuticals Company, Limited Method of promoting nucleic acid transfer
CA2557508C (en) * 2004-02-26 2016-08-16 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
ES2944067T3 (en) 2005-10-26 2023-06-19 Novartis Ag Use of anti-il-1beta antibodies
WO2008145664A1 (en) 2007-05-29 2008-12-04 Novartis Ag New indications for anti- il-i-beta therapy
US9028553B2 (en) 2009-11-05 2015-05-12 DePuy Synthes Products, Inc. Self-pivoting spinal implant and associated instrumentation
EP2627173B2 (en) 2010-10-12 2018-07-04 Chiesi Farmaceutici S.p.A. Clevidipine emulsion formulations containing antimicrobial agents
US10966843B2 (en) 2017-07-18 2021-04-06 DePuy Synthes Products, Inc. Implant inserters and related methods
US11045331B2 (en) 2017-08-14 2021-06-29 DePuy Synthes Products, Inc. Intervertebral implant inserters and related methods
CN114423413A (en) * 2019-07-02 2022-04-29 俄亥俄州国家创新基金会 Neurodegenerative disease therapy using the skin-brain axis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235890A1 (en) * 2001-11-19 2003-12-25 David Wyllie Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5350683A (en) * 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US6156304A (en) * 1990-12-20 2000-12-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for studying and treating a connective tissue of a mammalian host
US6413511B1 (en) * 1990-12-20 2002-07-02 University Of Pittsburgh Of The Commonwealth System Of Higher Education Cartilage alterations by administering to joints chondrocytes comprising a heterologous polynucleotide
EP0547699A1 (en) 1991-12-19 1993-06-23 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
JP3386125B2 (en) 1992-02-21 2003-03-17 メルク エンド カンパニー インコーポレーテッド Peptidyl derivatives as interleukin-1β converting enzyme inhibitors
EP0628550B1 (en) 1993-06-08 1998-02-25 Sanofi Pyridazines as interleukin-1beta converting enzyme inhibitors
US5747072A (en) * 1993-07-30 1998-05-05 University Of Michigan Adenoviral-mediated gene transfer to synovial cells in vivo
EP0690673A4 (en) 1993-12-14 1996-05-29 Univ Pittsburgh Systemic gene treatment of connective tissue diseases
KR960700917A (en) * 1994-01-12 1996-02-24 마르 레메이르 IGNITING MEMBER FOR A CIGARETTE LIGHTER, PARTICULARLY IN A MOTOR VEHICLE
US6268140B1 (en) * 1994-02-03 2001-07-31 Neugenesis Combinatorial metabolic libraries
IT1269989B (en) 1994-09-21 1997-04-16 Dompe Spa IL-1 RECEPTOR ANTAGONISTS WITH INCREASED INHIBITORY ACTIVITY
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6573366B1 (en) * 1996-06-07 2003-06-03 Gruppo Lepetit S.P.A. Process for the purification of human interleukin-1 receptor antagonist from recombinant E. coli
US5780513A (en) * 1996-08-22 1998-07-14 Washington University Method of inhibiting the release of bioactive IL-1
US6197551B1 (en) * 1998-01-27 2001-03-06 Millennium Pharmaceuticals, Inc. Spoil-1 protein and nucleic acid molecules and uses therefor
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
DE19741051A1 (en) * 1997-09-18 1999-03-25 Bayer Ag New tetrahydroquinoline derivatives useful in treatment of raised lipid levels and arteriosclerosis
US5992573A (en) 1997-09-24 1999-11-30 Blain; Roy W. Elevator up start
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6387953B1 (en) * 1999-03-18 2002-05-14 Brigham And Women's Hopsital Inhibition of TNF-(α)-initiated neutrophil response
EP2329842A3 (en) 2000-05-12 2011-07-27 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
NZ533223A (en) * 2001-11-14 2007-04-27 Centocor Inc Anti-il-6 antibodies, compositions, methods and uses
AU2003248102A1 (en) * 2002-07-25 2004-02-16 Toshiba Tec Kabushiki Kaisha Vacuum cleaner
CA2557508C (en) * 2004-02-26 2016-08-16 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
JP5022216B2 (en) * 2004-06-04 2012-09-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Methods of using IL-1 antagonists for treating autoinflammatory diseases
US7466175B2 (en) 2006-12-29 2008-12-16 Motorola, Inc. Capacitance multiplier circuit

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235890A1 (en) * 2001-11-19 2003-12-25 David Wyllie Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KWON K.M. ET AL: "Suppressive Effects of Natural and Synthetic Agents on Dextran Sulfate Sodium-induced Interleukin-1 beta from Murine Pderitoneal Macrophages", BIOSCI. BIOTECHNOL. BIOCHEM., vol. 68, no. 2, February 2004 (2004-02-01), pages 436 - 439, XP002992708 *

Also Published As

Publication number Publication date
US20080160032A1 (en) 2008-07-03
AU2010214641B2 (en) 2012-07-05
WO2005082070A2 (en) 2005-09-09
AU2005216298B2 (en) 2010-09-02
US20080161424A1 (en) 2008-07-03
JP5814851B2 (en) 2015-11-17
EP1720893A4 (en) 2010-07-14
US8148346B2 (en) 2012-04-03
JP2007525524A (en) 2007-09-06
US20100069466A1 (en) 2010-03-18
US11406688B2 (en) 2022-08-09
US20140364327A1 (en) 2014-12-11
JP2015227356A (en) 2015-12-17
US20120258120A1 (en) 2012-10-11
US20230134568A1 (en) 2023-05-04
JP4989456B2 (en) 2012-08-01
US20120148498A1 (en) 2012-06-14
CN1946734B (en) 2012-07-18
CA2557508C (en) 2016-08-16
EP2784090A1 (en) 2014-10-01
US7615212B2 (en) 2009-11-10
AU2005216298A1 (en) 2005-09-09
CN1946734A (en) 2007-04-11
ES2523147T3 (en) 2014-11-21
CA2557508A1 (en) 2005-09-09
US20170281730A1 (en) 2017-10-05
US20050192241A1 (en) 2005-09-01
AU2010214641C1 (en) 2015-04-23
AU2010214641A1 (en) 2010-09-16
US7622110B2 (en) 2009-11-24
US20100068201A1 (en) 2010-03-18
US10716832B2 (en) 2020-07-21
DK1720893T3 (en) 2014-11-24
US9649361B2 (en) 2017-05-16
US8221748B2 (en) 2012-07-17
US20160067310A1 (en) 2016-03-10
EP1720893B1 (en) 2014-08-13
EP1720893A2 (en) 2006-11-15
US20200345813A1 (en) 2020-11-05
US20080161262A1 (en) 2008-07-03
JP2012162552A (en) 2012-08-30

Similar Documents

Publication Publication Date Title
WO2005082070A3 (en) Compositions and methods for the systemic treatment of arthritis
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
WO2007066150A3 (en) Transdermal administration of active agents for systemic effect
HK1073997A1 (en) Administration of agents for the treatment of inflammation
WO2005107726A3 (en) Method for the treatment of back pain
WO2004110368A3 (en) Combination therapy for the treatment of hypertension
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
WO2008011392A8 (en) Proline urea ccr1 antagonists for the treatment of autoimmune diseases or inflammation
WO2004052280A3 (en) Anti-angiogenic compounds and their use in cancer treatment
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
NO20062198L (en) Bradykinin B1 receptor antagonists
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
WO2007093183A3 (en) Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases
WO2006036770A3 (en) Combination therapy for the treatment of obesity
IL190632A0 (en) Biphenyl derivatives and pharmaceutical compositions containing the same
WO2004006859A3 (en) Platinum compound
WO2008029237A3 (en) Combination therapies for rheumatoid arthritis
WO2006098979A3 (en) Aminopterin dosage forms and methods for inflammatory disorders
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2008040774A3 (en) Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats
WO2009015063A8 (en) Methods and compositions for treating fibrosis related disorders using il-17 antagonists
MXPA04001397A (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate.
WO2005092062A3 (en) Compounds for neurodegenerative disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2557508

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007501027

Country of ref document: JP

Ref document number: 2005216298

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005723881

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005216298

Country of ref document: AU

Date of ref document: 20050225

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005216298

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580012832.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005723881

Country of ref document: EP